Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Starpharma Holdings Limited (ASX:SPL) Announce Final Report and Annual Results

Abstract:
Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced its full year financial results for the year ended 30 June 2008.

Starpharma Holdings Limited (ASX:SPL) Announce Final Report and Annual Results

Melbourne, Australia | Posted on August 27th, 2008

Total operating and investing outflows for the year were A$5.4 million, and at the end of June 2008 the Company held cash reserves of A$7.5 million. Net cash outflows for the year of A$2.0 million included a financing inflow of A$3.4 million.

The net loss for the period was A$7.5 million, compared with A$7.2 million for the previous year.

Revenue from ordinary activities increased by 17% to A$1.7 million over the period, consisting of royalty and licensing revenue of A$1.4 million, and interest revenue on cash held. Other income of A$8.2 million consisted of grant income from United States and Australian Government grants. The majority of US Government grants were from the National Institutes of Health (NIH).

Further details of the financial results are included in the Preliminary Final Report to Australian Securities Exchange (ASX).

During this reporting period the Company has made substantial progress as highlighted by the following announcements over the year:

Commercial development

- The signing of an agreement with leading condom company SSL International plc, owner of the Durex(R) brand, for co-development of VivaGel(R)-coated condoms.

- The signing of a collaborative research agreement with Stiefel - the world's largest privately-owned dermatology pharmaceutical company.

- First commercial product launch of Priostar(R) Dendrimers - EMD Chemicals Inc. launch a research reagent kit called NanoJuiceTM Transfection Kit. VivaGel(R): Clinical Development and New Indications

- Clinical trial demonstrates that VivaGel(R) is safe and well-tolerated in women following twice daily dosing for 14 days - 54 sexually abstinent women tested in double-blind study in US and Kenya.

- Potential to expand VivaGel(R) applications to genital warts and cervical cancer - pre-clinical data demonstrates the active ingredient in VivaGel(R), SPL7013, inhibits clinically-relevant strains of human papillomavirus (HPV).

Pipeline and Application development

- SPL7013, the active ingredient in VivaGel(R), found to have potential application for arthritis and dermatology treatments.

- Starpharma and Baker IDI Heart and Diabetes Institute awarded funding for codevelopment of arterial disease imaging agent.

- US$1.3 million US Defense Department contract awarded to DNT and Central Michigan University Research Corporation to develop water purification technology.

- Dendrimer technology applications expanded to food science with Unilever agreement to co-develop a research tool using Starpharma's Priostar(R) dendrimer technology.

####

About Starpharma Holdings Limited
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

For more information, please click here

Contacts:
Dr Jackie Fairley
Chief Executive Officer
TEL: +61-3-8532-2704

Copyright © Starpharma Holdings Limited

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Renishaw receives Queen's Award for spectroscopy developments November 25th, 2014

JPK reports on the use of AFM and the CellHesion module to study plant cells at the University of Queensland November 25th, 2014

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research yields material made of single-atom layers that snap together like Legos November 25th, 2014

Nanomedicine

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research reveals how our bodies keep unwelcome visitors out of cell nuclei November 24th, 2014

ASU, IBM move ultrafast, low-cost DNA sequencing technology a step closer to reality November 24th, 2014

An Inside Job: UC-Designed Nanoparticles Infiltrate, Kill Cancer Cells From Within November 24th, 2014

Announcements

Renishaw receives Queen's Award for spectroscopy developments November 25th, 2014

JPK reports on the use of AFM and the CellHesion module to study plant cells at the University of Queensland November 25th, 2014

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research yields material made of single-atom layers that snap together like Legos November 25th, 2014

Financial Reports

Harris & Harris Group Reports Financial Statements as of September 30, 2014 November 11th, 2014

Harris & Harris Group to Host Conference Call on Third Quarter 2014 Financial Results on November 12, 2014 November 3rd, 2014

Aspen Aerogels, Inc. Schedules Third Quarter 2014 Earnings Release and Conference Call for November 6, 2014 October 17th, 2014

Nanometrics to Announce Third Quarter Financial Results on October 28, 2014 October 8th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE